Related references
Note: Only part of the references are listed.Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
P. Garcia-Alfonso et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2022)
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy
Faisal Shakeel et al.
PHARMACOGENOMICS (2021)
Expanding evidence leads to new pharmacogenomics payer coverage
Philip E. Empey et al.
GENETICS IN MEDICINE (2021)
Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis
Bhavina B. Sharma et al.
ONCOLOGIST (2021)
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines
Carin A. T. C. Lunenburg et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2020)
Knowledge and attitudes on pharmacogenetics among pediatricians
Shahad Rahawi et al.
JOURNAL OF HUMAN GENETICS (2020)
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
Forike K. Martens et al.
FRONTIERS IN PHARMACOLOGY (2020)
Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity COMMENT
Daniel L. Hertz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
G. Argiles et al.
ANNALS OF ONCOLOGY (2020)
All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide
Federico Innocenti et al.
JCO ONCOLOGY PRACTICE (2020)
DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
Theodore J. Wigle et al.
PHARMACEUTICS (2019)
Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists
Marie-Anne Loriot et al.
BULLETIN DU CANCER (2019)
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice
Giuseppe Toffoli et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis
Linda M. Henricks et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M. Henricks et al.
LANCET ONCOLOGY (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Ursula Amstutz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer
Manon Launay et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time
Carin A. T. C. Lunenburg et al.
EUROPEAN JOURNAL OF CANCER (2016)
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Maarten J. Deenen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks et al.
LANCET ONCOLOGY (2015)
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)
Adam M. Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Cancer pharmacogenomics, adoption by oncologists and patient benefit
Lynn G. Dressler et al.
PERSONALIZED MEDICINE (2014)
Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey
E. J. Stanek et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
Lori Kay Mattison et al.
CLINICAL CANCER RESEARCH (2006)
Share Paper
